NEW YORK (GenomeWeb) – Almac Diagnostics today announced a collaboration with Illumina to establish a framework for developing next-generation sequencing-based companion diagnostic assays.

Under the terms of the agreement, UK-based Almac will be able to develop NGS assays using the Illumina MiSeqDx instrument. The MiSeqDx is the first NGS instrument to be cleared by the US Food and Drug Administration for in vitro diagnostic purposes in clinical laboratories.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.